ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
디지털/전기 혈압계 시장 규모는 2023년 9억 7,778만 달러에서 2024-2030년의 예측 기간 중 CAGR 10.57%로 추이하며, 2030년에는 17억 8,388만 달러에 달할 것으로 예측됩니다.
고혈압 및 기타 순환기 질환의 발생률 증가로 인해 정기적인 혈압 모니터링에 대한 수요가 증가하면서 디지털/전기 혈압계 시장을 주도하고 있습니다. 이러한 질환은 위험을 관리하기 위해 지속적인 모니터링이 필요한 경우가 많기 때문에 가정용 기기에 대한 의존도가 높아지고 있습니다. 건강에 대한 인식이 높아짐에 따라 정기적인 모니터링이 증가하고 있으며, 디지털 혈압계는 사용 편의성과 휴대성으로 인기를 끌고 있습니다. 또한 블루투스 연결, 스마트폰 연동 등 지속적인 기술 혁신은 소비자와 의료진 모두에게 더욱 매력적으로 다가서며 시장 성장을 더욱 촉진하고 있습니다. 이러한 치료 옵션의 확대와 경쟁 심화는 환자 치료 결과를 개선하고 2024-2030년 시장 성장을 가속할 것으로 예상됩니다.
디지털/전기 혈압계 시장 역학 :
세계보건기구(WHO)의 2023년 최신 데이터에 따르면 전 세계 30세에서 79세 사이의 성인 중 약 12억 8,000만 명이 고혈압을 앓고 있으며, 이들 중 대다수(3분의 2)는 중저소득 국가에 거주하고 있습니다. 고혈압을 앓고 있는 성인의 약 46%는 자신의 증상을 인지하지 못하고 있으며, 절반 이하(42%)만이 진단을 받고 치료를 받고 있는 것으로 나타났습니다.
British Heart Foundation의 2024년 최신 데이터에 따르면 전 세계에서 약 6억 2,000만 명(약 13명 중 1명)이 심장 및 순환기 질환을 앓고 있습니다. 또한 2021년 심장 및 순환기 질환 유병률은 유럽에서 1억 명, 아시아와 호주에서 3억 4,000만 명으로 집계되었습니다. 또한 허혈성 관상동맥 심장질환은 전 세계에서 가장 많이 진단되는 질환으로 약 2억 명이 앓고 있는 것으로 추산됩니다. 약 1억 1,000만 명의 남성과 8,000만 명의 여성이 이 질환을 앓고 있습니다.
고혈압은 심장마비, 뇌졸중, 심부전 등 다양한 심혈관 질환의 주요 위험 요소이기 때문에 이러한 질환을 효과적으로 관리하기 위해 혈압을 정기적으로 정확하게 모니터링해야 할 필요성이 높아지고 있습니다. 따라서 디지털 혈압계는 사용자 친화적인 인터페이스, 휴대성, 광범위한 의료 교육 없이도 신뢰할 수 있는 측정값을 제공할 수 있는 능력을 갖춘 디지털 혈압계는 환자와 의료진 모두에게 필수적인 툴이 되어 세계 디지털/전기 혈압계 시장을 확대시키고 있습니다.
상기 요인 외에도 진단 정확도를 높이는 신기술 개발 등 디지털/전기 혈압계 분야의 기술 발전도 디지털/전기 혈압계 시장의 성장에 도움이 될 것으로 예상됩니다.
세계의 디지털/전기 혈압계 시장을 조사했으며, 시장 개요, 시장 영향요인 및 시장 기회 분석, 법규제 환경, 시장 규모 추이·예측, 각종 구분·지역/주요 국가별 상세 분석, 경쟁 구도, 주요 기업의 개요 등을 정리하여 전해드립니다.
목차
제1장 디지털/전기 혈압계 시장 : 서론
제2장 디지털/전기 혈압계 시장 : 개요
제3장 경쟁 구도
제4장 규제 분석
미국
유럽
일본
중국
제5장 디지털/전기 혈압계 시장 : 주요 요인 분석
시장 성장 촉진요인
고혈압, 심혈관질환, 기타 순환기계 질환의 발생률 증가
건강에 대한 의식의 향상
디지털/전기 혈압계 분야에서 기술 진보의 진전
시장 성장 억제요인·과제
디지털/전기 혈압계에 관한 정도 우려
혈압계의 지속적 재교정의 필요성
시장 기회
웨어러블 디바이스의 출현·원격 환자 모니터링으로의 이동 증가
제6장 디지털/전기 혈압계 시장 : Porter's Five Forces 분석
제7장 디지털/전기 혈압계 시장 : 시장 평가
제품 유형별
상완
손목
기술별
완전 자동
반자동
포터빌리티
휴대용
비휴대용
최종사용자별
병원·클리닉
외래 진료 센터
홈케어
기타
지역별
북미
유럽
아시아태평양
기타 지역
제8장 디지털/전기 혈압계 시장 : 기업·제품 개요
OMRON Healthcare, Inc.
Hill-Rom Services, Inc.
A&D Company Limited
SunTech Medical, Inc.
American Diagnostic Corporation
Withings
General Electric Company
Microlife Corporation
GF Health Products, Inc.
Spacelabs Healthcare
Rudolf Riester GmbH
Contec Medical Systems Co., Ltd.
ARCHOS(TM)
Panasonic Corporation
Yuwell-Jiangsu Yuyue medical equipment & supply Co., Ltd.
ERKA Kallmeyer Medizintechnik GmbH & Co. KG.
BOSCH + SOHN GmbH u. Co. KG.
Beijing Choice Electronic Tech Co., Ltd.
Koninklijke Philips N.V.
SPENGLER HOLTEX Group
제9장 KOL의 견해
제10장 프로젝트 어프로치
제11장 DelveInsight 소개
제12장 면책사항·문의
KSA
영문 목차
영문목차
Digital/Electrical Sphygmomanometer Market by Product Type (Upper Arm and Wrist Type), Technology (Full-Automatic and Semi-Automatic), Portability (Portable and Non-Portable), End-User (Hospitals & Clinics, Ambulatory Care Centers, Home Care Settings, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2030 owing to the increase in incidence of hypertension, other circulatory system disorders, and growing technological advancements in the field of digital/electrical sphygmomanometer.
The global digital/electrical sphygmomanometer market was valued at USD 977.78 million in 2023, growing at a CAGR of 10.57% during the forecast period from 2024 to 2030 to reach USD 1,783.88 million by 2030. The increasing incidence of hypertension and other circulatory disorders has fueled the demand for regular blood pressure monitoring, driving the market for digital/electrical sphygmomanometers. These disorders often require continuous monitoring to manage risks, which increases reliance on home-use devices. Increased health awareness is boosting regular monitoring, making digital sphygmomanometers popular for their ease of use and portability. Additionally, continuous innovations, such as bluetooth connectivity and smartphone integration, are enhancing their appeal to both consumers and healthcare providers, further propelling market growth. This expansion of treatment options and increased competition enhances patient outcomes and propels market growth from 2024 to 2030.
As per the latest data provided by World Health Organization (2023), an estimated 1.28 billion adults aged 30-79 years worldwide had hypertension, with most (two-thirds) residing in low- and middle-income countries. An estimated 46% of adults with hypertension were unaware of their condition, and less than half (42%) had been diagnosed and treated.
According to a recent data provided by British Heart Foundation (2024), globally, approximately 620 million people, or about 1 in 13 individuals, lived with heart and circulatory diseases. Additionally, as per the same source, the prevalence of heart and circulatory diseases was 100 million in Europe and 340 million in Asia and Australia in 2021. Furthermore, as per the recent data provided by the British Heart Foundation (2024), coronary (ischemic) heart disease, was the most commonly diagnosed worldwide, affected an estimated 200 million people globally. Approximately 110 million men and 80 million women were affected. Additionally, around 56 million women and 45 million men were stroke survivors. It was estimated that at least 13 million people worldwide lived with congenital heart disease, with potentially millions more undiagnosed.
As hypertension is a major risk factor for various cardiovascular conditions, including heart attacks, strokes, and heart failure, there is an increasing need for regular and accurate monitoring of blood pressure to manage these diseases effectively. Thus, digital sphygmomanometers, with their user-friendly interfaces, portability, and ability to provide reliable readings without requiring extensive medical training, have become indispensable tools for both patients and healthcare providers thereby escalating the overall market of digital/electrical sphygmomanometer across the globe.
Along with the factors mentioned above, technological advancements in the field of digital/electrical sphygmomanometer such as the development of new techniques to enhance the yield and diagnostic accuracy are also expected to aid in the growth of the digital/electrical sphygmomanometer market. For instance, in January 2022, Aktiia announced a landmark hypertension trial in the United States in collaboration with a top US hypertension center, for its world's 24/7 blood pressure monitor, which automatically gathers over 100x the data and has over 10x the engagement of other blood pressure monitors.
However, digital/electrical sphygmomanometer being very sensitive due to which body movements affect its accuracy and the need for continuous recalibration of the devices may be certain limiting factors of the digital/electrical sphygmomanometer market growth.
Digital/Electrical Sphygmomanometer Market by Product Type (Upper Arm and Wrist Type), Technology (Full-Automatic and Semi-Automatic), Portability (Portable and Non-Portable), End-User (Hospitals & Clinics, Ambulatory Care Centers, Home Care Settings, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)
In the product type segment of the overall digital/electrical sphygmomanometer market, the wrist type digital/electrical sphygmomanometer are expected to hold the largest share in the year 2023. Wrist-worn digital/electrical sphygmomanometers are playing a significant role in boosting the overall market for blood pressure monitoring devices. Their unique design and user-friendly features cater to a growing demand for convenience, portability, and real-time health monitoring, contributing to their increasing popularity among consumers and healthcare providers alike.
Additionally, the primary advantages of wrist-worn sphygmomanometers is their portability. Wrist-worn models are compact and lightweight, making them ideal for users who need to monitor their blood pressure regularly while on the go. This convenience appeals to a broad range of consumers, including those who travel frequently or have busy lifestyles, thereby expanding the market reach of digital sphygmomanometers. These devices are typically easier to position and operate than their upper-arm counterparts, which can be especially beneficial for elderly users or individuals with limited mobility. The simplicity of wrist-worn sphygmomanometers encourages more frequent monitoring, aligning with the growing trend of proactive health management. As people become more aware of the importance of tracking their blood pressure regularly to prevent or manage conditions like hypertension, the demand for user-friendly, accessible devices increases, further boosting the market.
Furthermore, the technological advancements in wrist-worn digital sphygmomanometers are also contributing to their rising popularity. Modern devices often feature integration with smartphones and other digital health platforms, allowing users to easily track and analyze their blood pressure data over time. This ability to monitor trends and share data with healthcare providers enhances the utility of wrist-worn devices, making them an attractive option for tech-savvy consumers and those managing chronic conditions. For instance, in June 2022, LiveMetric announced the launch of LiveOne, the world's first 510(k) FDA-cleared nano-sensor technology for continuous blood pressure monitoring. This wrist-worn, cuff-free device provided real-time measurements every 10 seconds, improving care for hypertension and cardiovascular patients. Hence, all the above-mentioned factors are expected to generate considerable revenue of the segment pushing the overall growth of the global digital/electrical sphygmomanometer market during the forecast period.
North America is expected to dominate the overall digital/electrical sphygmomanometer market:
Among all the regions, North America is expected to hold the largest share in the global digital/electrical sphygmomanometer market in 2023. Owing to significant growth factors such as hypertension, cardiovascular diseases. Additionally, increasing health awareness, rising government initiatives, and increasing product launches and product approvals are expected to aid in the growth of the North American digital/electrical sphygmomanometer market during the forecast period from 2024 to 2030.
According to the latest data provided by the Centre for Disease Control and Prevention (2023), approximately, 48.1% population of adults age 18 and older in the United States are living with hypertension. Additionally, as per the recent data from the Centers for Disease Control and Prevention (2024), approximately 4.9% of adults were diagnosed with coronary heart disease in 2022. Furthermore, by 2023, an estimated 12.1 million individuals in the United States were projected to have atrial fibrillation. Additionally, each year, over 795,000 people in the U.S. experience a stroke, with around 610,000 of these being first-time strokes. Notably, nearly 185,000 of these strokes, or about one in four, occur in individuals who have previously had a stroke. With hypertension being a critical risk factor for cardiovascular conditions, including heart attacks, strokes, and heart failure, there is an escalating need for reliable and consistent blood pressure monitoring. Digital sphygmomanometers, with their user-friendly design, portability, and precision, have become indispensable for effective disease management. This trend is accelerating the growth of the digital/electrical sphygmomanometers across the region.
Furthermore, the increased emphasis on product development activities and high interest of device manufacturers in accessing local markets further aid in the growth of the regional markets for digital/electrical sphygmomanometer. For instance, in March 2021, Qardio, Inc. announced the US Food and Drug Administration (FDA) 510k clearance for its QardioCore ambulatory ECG device.
Therefore, the above-mentioned factors are expected to bolster the growth of the digital/electrical sphygmomanometer market in the North America during the forecast period.
Some of the key market players operating in the Digital/Electrical Sphygmomanometer market include OMRON Healthcare, Inc., Hill-Rom Services, Inc., A&D Company Limited, SunTech Medical, Inc., American Diagnostic Corporation, Withings, General Electric Company, Microlife Corporation, GF Health Products, Inc., Spacelabs Healthcare, Rudolf Riester GmbH, Contec Medical Systems Co., Ltd., ARCHOS(TM), Panasonic Corporation, Yuwell-Jiangsu Yuyue medical equipment & supply Co., Ltd., ERKA Kallmeyer Medizintechnik GmbH & Co. KG., BOSCH + SOHN GmbH u. Co. KG., Beijing Choice Electronic Tech Co., Ltd, Koninklijke Philips N.V., SPENGLER HOLTEX Group, and others.
Recent Developmental Activities in the Digital/Electrical Sphygmomanometer Market:
In January 2024, Nanowear announced the FDA 510(k) clearance for SimpleSense-BP, AI-enabled continuous blood pressure monitoring and for hypertension diagnostic management.
In August 2023, Corsano Health launched CardioWatch EU-MDR , a cuffless blood pressure monitor.
In September 2022, Gramin received FDA clearance for smart BPM Smart Blood Pressure Monitor.
In August 2022, Sensifree Ltd. Received CE certificate for SentiCor-100(R) in compliance with the new EU MDR.
In February 2022, Abbott announced the US Food and Drug Administration (FDA) approval of an expanded indication for its CardioMEMS(TM) HF System to support the care of more people living with heart failure. The sensor provides an early warning system enabling doctors to protect against worsening heart failure.
Key Takeaways From the Digital/Electrical Sphygmomanometer Market Report Study:
Market size analysis for current digital/electrical sphygmomanometer size (2023), and market forecast for 6 years (2024 to 2030)
Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
Key companies dominating the digital/electrical sphygmomanometer market.
Various opportunities available for the other competitors in the digital/electrical sphygmomanometer market space.
What are the top-performing segments in 2023? How these segments will perform in 2030?
Which are the top-performing regions and countries in the current digital/electrical sphygmomanometer market scenario?
Which are the regions and countries where companies should have concentrated on opportunities for digital/electrical sphygmomanometer market growth in the coming future?
Target Audience who can be Benefited From This Digital/Electrical Sphygmomanometer Market Report Study:
Digital/electrical sphygmomanometer -related organizations, associations, forums, and other alliances
Government and corporate offices
Start-up companies, venture capitalists, and private equity firms
Distributors and traders dealing in digital/electrical sphygmomanometer
Various end-users who want to know more about the digital/electrical sphygmomanometer market and the latest technological developments in the digital/electrical sphygmomanometer market.
Frequently Asked Questions for the Digital/Electrical Sphygmomanometer Market:
1. What are digital/electrical sphygmomanometer?
Sphygmomanometers are medical devices that are used to measure blood pressure (mainly in arteries). These devices are of three types mainly mercury sphygmomanometers, an aneroid sphygmomanometer, and electronic/digital sphygmomanometer.
2. What is the market for digital/electrical sphygmomanometer?
The global digital/electrical sphygmomanometer market was valued at USD 977.78 million in 2023, growing at a CAGR of 10.57% during the forecast period from 2024 to 2030 to reach USD 1,783.88 million by 2030.
3. What are the drivers for the digital/electrical sphygmomanometer market?
The rising incidence of hypertension and other circulatory system disorders has driven demand for accurate, user-friendly blood pressure monitors. Increased health awareness is boosting regular monitoring, making digital sphygmomanometers popular for their ease of use and portability. Additionally, continuous innovations, such as bluetooth connectivity and smartphone integration, are enhancing their appeal to both consumers and healthcare providers, further propelling market growth. This expansion of treatment options and increased competition enhances patient outcomes and propels market growth from 2024 to 2030.
4. Who are the key players operating in the digital/electrical sphygmomanometer market?
Some of the key market players operating in the digital/electrical sphygmomanometer market include OMRON Healthcare, Inc., Hill-Rom Services, Inc., A&D Company Limited, SunTech Medical, Inc., American Diagnostic Corporation, Withings, General Electric Company, Microlife Corporation, GF Health Products, Inc., Spacelabs Healthcare, Rudolf Riester GmbH, Contec Medical Systems Co., Ltd., ARCHOS(TM), Panasonic Corporation, Yuwell-Jiangsu Yuyue medical equipment & supply Co., Ltd., ERKA Kallmeyer Medizintechnik GmbH & Co. KG., BOSCH + SOHN GmbH u. Co. KG., Beijing Choice Electronic Tech Co., Ltd., Koninklijke Philips N.V., SPENGLER HOLTEX Group and others.
5. Which region has the highest share in the digital/electrical sphygmomanometer market?
Among all the regions, North America is expected to hold the largest share in the global digital/electrical sphygmomanometer market in 2023. Owing to significant growth factors such as hypertension, cardiovascular diseases, increasing health awareness, rising government initiatives, and increased government product regulations are expected to aid in the growth of the North American digital/electrical sphygmomanometer market during the forecast period from 2024 to 2030.
